Clement MS, Ebert EBF, Meldgaard P, Sorensen BS, et al. Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. Clin Lung Cancer 2021;22:e870-e877.
PMID: 34140247